The global antiviral drugs market, valued at USD 49.6 billion in 2022, is expected to witness steady growth, reaching USD 66.53 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 3.74% during the forecast period from 2023 to 2030.
The rising prevalence of viral infections, coupled with advancements in drug development technologies, is fueling the growth of the antiviral drugs market. Additionally, the ongoing COVID-19 pandemic has further accelerated the demand for antiviral medications, driving significant investments in research and development.
Key Players
The major key players are Gilead Sciences Inc., AbbVie, Inc., GlaxoSmithKline, Merck& C.O., Inc., Jannssen Pharmaceuticals, Inc., Bristol- Meyrs Squibb Company, Mylan N. V., Novartis AG, AstraZeneca Plc Company Profile, Pfizer Inc., Cipla Inc., Johnson & Johnson Services, Inc. and others.
Market Analysis:
The antiviral drugs market is segmented based on drug class, indication, route of administration, and region. Key drug classes include DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. Indications encompass HIV/AIDS, hepatitis, influenza, herpes, and others. By route of administration, the market is categorized into oral, topical, intravenous, and others.
KEY SEGMENTS
By Drug Class
By Disease Indication
By Distribution Channel
-
Hospital Pharmacy
-
Retail Pharmacy
-
Online Pharmacy
Impact of the Russia-Ukraine Conflict:
The Russia-Ukraine conflict has raised concerns about disruptions in the pharmaceutical supply chain, potentially affecting the availability of antiviral drugs globally. With Ukraine being a significant producer of active pharmaceutical ingredients (APIs), any disturbances in the region could lead to supply shortages and price fluctuations in the market.
The Impact of Economic Slowdown:
The global economic slowdown resulting from the COVID-19 pandemic has impacted healthcare spending and investment in research and development. However, the essential nature of antiviral medications, particularly in managing infectious diseases, has mitigated some of these effects. Governments and healthcare organizations continue to prioritize the procurement of antiviral drugs, supporting market growth.
Regional Analysis:
North America currently dominates the antiviral drugs market, driven by a high prevalence of viral infections, robust healthcare infrastructure, and significant investments in drug development. However, Asia Pacific is poised to witness substantial growth during the forecast period, attributed to increasing healthcare expenditure, rising awareness about viral diseases, and expanding pharmaceutical manufacturing capabilities.
Key Takeaways:
- The global antiviral drugs market is projected to reach USD 66.53 billion by 2030, driven by the rising prevalence of viral infections and advancements in drug development technologies.
- The Russia-Ukraine conflict may disrupt the pharmaceutical supply chain, impacting the availability and pricing of antiviral medications worldwide.
- Despite the economic slowdown, the essential nature of antiviral drugs is expected to sustain market growth, supported by continued government spending and healthcare investments.
- North America currently leads the market, while Asia Pacific is anticipated to emerge as a significant growth region during the forecast period.
As the demand for antiviral drugs continues to rise, pharmaceutical companies are focusing on innovation and strategic collaborations to meet the evolving healthcare needs and address emerging viral threats
Other Trending Report
Human Papillomavirus (HPV) Vaccine Market Trends
Antiviral Drugs Market Trends
Bovine Mastitis Market Trends
Recombinant Vaccines Market Trends
Ureteroscope Market Trends
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Akash Anand – Head of Business Development & Strategy
info@snsinsider.com
Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)
Website: https://www.snsinsider.com